Science Explorer Back to mapMap
Discussion
Company · Lexington · United States

Synageva BioPharma (United States)

synageva.comROR OpenAlex
Research works
14
▲ 116% vs 2018-21
Citations
180
12.8 per fractional work
Top-10% rate
4.6%
all institutions 10.0%
Open access
26%
world 40%
International
40%
world 18%
Synageva BioPharma (United States)

Not ranked overall: Synageva BioPharma (United States) is under the volume floor below which a citation excellence rate is noise. Not ranked is not the same as ranked last.

Which fields of science does Synageva BioPharma (United States) work in?

In all years, 65% of research at Synageva BioPharma (United States) is in Health Sciences, 25% in Life Sciences. Its largest fields are Medicine (64%), Biochemistry, Genetics and Molecular Biology (15%), Immunology and Microbiology (8%). It does 1.9× the world's share of Health Sciences.

Health Sciences: 9 fractional works · 64.9% of its workMedicine: 9 fractional works · 63.8% of its workPhysiology: 4 fractional works · 26.9% of its workPathology and Forensic Medicine: 1 fractional works · 6.5% of its workEpidemiology: 1 fractional works · 6.1% of its workRadiology, Nuclear Medicine and Imaging: 1 fractional works · 4.8% of its workSurgery: 1 fractional works · 4.1% of its workInfectious Diseases: 0 fractional works · 3.1% of its workPediatrics, Perinatology and Child Health: 0 fractional works · 2.8% of its workRheumatology: 0 fractional works · 2.3% of its workOncology: 0 fractional works · 2.3% of its workGenetics: 0 fractional works · 1.2% of its workHematology: 0 fractional works · 0.9% of its workPublic Health, Environmental and Occupational Health: 0 fractional works · 0.9% of its workCardiology and Cardiovascular Medicine: 0 fractional works · 0.8% of its workPulmonary and Respiratory Medicine: 0 fractional works · 0.6% of its workNeurology: 0 fractional works · 0.4% of its workVeterinary: 0 fractional works · 0.8% of its workSmall Animals: 0 fractional works · 0.8% of its workNursing: 0 fractional works · 0.4% of its workNutrition and Dietetics: 0 fractional works · 0.4% of its workLife Sciences: 3 fractional works · 24.5% of its workBiochemistry, Genetics and Molecular Biology: 2 fractional works · 14.7% of its workPhysiology: 1 fractional works · 5.5% of its workMolecular Biology: 1 fractional works · 4.3% of its workCell Biology: 0 fractional works · 1.8% of its workGenetics: 0 fractional works · 1.3% of its workBiochemistry: 0 fractional works · 1.2% of its workClinical Biochemistry: 0 fractional works · 0.8% of its workImmunology and Microbiology: 1 fractional works · 7.9% of its workImmunology: 1 fractional works · 7.9% of its workPharmacology, Toxicology and Pharmaceutics: 0 fractional works · 1.2% of its workPharmaceutical Science: 0 fractional works · 1.2% of its workNeuroscience: 0 fractional works · 0.7% of its workNeurology: 0 fractional works · 0.4% of its workSensory Systems: 0 fractional works · 0.4% of its workPhysical Sciences: 1 fractional works · 10.4% of its workChemistry: 1 fractional works · 6.3% of its workOrganic Chemistry: 1 fractional works · 6.3% of its workEngineering: 0 fractional works · 2.3% of its workElectrical and Electronic Engineering: 0 fractional works · 2.3% of its workMaterials Science: 0 fractional works · 1.2% of its workElectronic, Optical and Magnetic Materials: 0 fractional works · 1.2% of its workMathematics: 0 fractional works · 0.6% of its workModeling and Simulation: 0 fractional works · 0.6% of its workSocial Sciences: 0 fractional works · 0.2% of its workEconomics, Econometrics and Finance: 0 fractional works · 0.2% of its workALL ITS WORKSynagevaBioPharma (Unite…14fractional works, all years
Life Sciences25%Physical Sciences10%Health Sciences65%Social Sciences0%

Each ring splits the one inside it: the four domains of science, their fields, their subfields. Size is fractional works in all years. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 4 domains and 12 fields, with their numbers
    1. Medicine963.8%
    2. Veterinary00.8%
    3. Nursing00.4%
    1. Biochemistry, Genetics and Molecular Biology214.7%
    2. Immunology and Microbiology17.9%
    3. Pharmacology, Toxicology and Pharmaceutics01.2%
    4. Neuroscience00.7%
    1. Chemistry16.3%
    2. Engineering02.3%
    3. Materials Science01.2%
    4. Mathematics00.6%
    1. Economics, Econometrics and Finance00.2%
All of science, and how each field's share has moved since 1950: the Science domain explorer

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Who are the top researchers at Synageva BioPharma (United States)?

Ranked on the quality score, Stephen Eckert, Anthony Quinn and Sandra Rojas-Caro lead among researchers whose main affiliation is Synageva BioPharma (United States).

  1. 1 Stephen Eckert United States · #533,637 worldwide 4.3k citations · 45 works
  2. 2 Anthony Quinn United States · #585,988 worldwide 7.3k citations · 149 works
  3. 3 Sandra Rojas-Caro United States · #1,890,242 worldwide 629 citations · 19 works
  4. 4 Radhika Tripuraneni United States · #2,260,898 worldwide 368 citations · 24 works
All ranked researchers at Synageva BioPharma (United States)

What are the most cited papers from Synageva BioPharma (United States)?

The most cited paper from Synageva BioPharma (United States) is "Lysosomal acid lipase deficiency – An under-recognized cause of dyslipidaemia and liver dysfunction" (Željko Reiner, Ornella Guardamagna, Devaki R. Nair et al., 2014), with 314 citations. Next come "A Phase 3 Trial of Sebelipase Alfa in Lysosomal Acid Lipase Deficiency" (248) and "Rapid progression and mortality of lysosomal acid lipase deficiency presenting in infants" (121).

Most cited papers
#PaperReleasedCitations
1 Lysosomal acid lipase deficiency – An under-recognized cause of dyslipidaemia and liver dysfunction Željko Reiner, Ornella Guardamagna, Devaki R. Nair et al. · Atherosclerosis Open access 15 Apr 2014 314
2 A Phase 3 Trial of Sebelipase Alfa in Lysosomal Acid Lipase Deficiency Barbara K. Burton et al. · New England Journal of Medicine Open access 10 Sep 2015 248
3 Rapid progression and mortality of lysosomal acid lipase deficiency presenting in infants Simon Allan Jones et al. · Genetics in Medicine Open access 27 Aug 2015 121
4 Clinical Effect And Safety Profile of Recombinant Human Lysosomal Acid Lipase in Patients With Cholesteryl Ester Storage Disease Manisha Balwani, Catherine Mary Breen, Gregory M. Enns et al. · Hepatology Open access 24 Jan 2013 119
5 Clinical Features of Lysosomal Acid Lipase Deficiency Barbara K. Burton, Patrick B. Deegan, Gregory M. Enns et al. · Journal of Pediatric Gastroenterology and Nutrition Open access 7 Aug 2015 116
All 49 most cited papers, with filters and sorting

Which research topics does Synageva BioPharma (United States) publish most on?

By volume in 2022-now: Respiratory viral infections research, Viral Infections and Outbreaks Research, Viral Infections and Vectors and COVID-19 epidemiological studies.

Respiratory viral infect…0Respiratory viral infections research: 0 fractional worksViral Infections and Outbreaks Research: 0 fractional worksViral Infections and Vec…0Viral Infections and Vectors: 0 fractional worksCOVID-19 epidemiological…0COVID-19 epidemiological studies: 0 fractional worksViral Infections and Immunology Research: 0 fractional worksViral gastroenteritis research and epidemiology: 0 fractional worksInfection Control and Ve…0Infection Control and Ventilation: 0 fractional works
EpidemiologyInfectious DiseasesModeling and SimulationCardiology and Cardiovascular Medicine1 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 Respiratory viral infections research Epidemiology 0 works
  2. 2 Viral Infections and Outbreaks Research Infectious Diseases 0 works
  3. 3 Viral Infections and Vectors Infectious Diseases 0 works
  4. 4 COVID-19 epidemiological studies Modeling and Simulation 0 works
  5. 5 Viral Infections and Immunology Research Cardiology and Cardiovascular Medicine 0 works
  6. 6 Viral gastroenteritis research and epidemiology Infectious Diseases 0 works
  7. 7 Infection Control and Ventilation Pulmonary and Respiratory Medicine 0 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available26.4%not open73.6%

World: 40% of research is openly available.

with international co-authors39.8%domestic only60.2%

World: 18% is written across borders.

How has Synageva BioPharma (United States)'s research output changed?

Output in 2022-2025 was 116% higher than in 2018-2021.

still counting2010201520202025
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Other research institutions in Lexington

All research institutions in Lexington

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about Synageva BioPharma (United States). Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.